The layoffs will affect 150 long-tenured salespeople in Gilead’s cardiopulmonary division, which markets two drugs, Ranexa and Letairis, which recently lost patent exclusivity.
The decision is unfortunate but necessary to cut costs, Gilead said. The drugmaker already warned investors that sales generated by the two drugs would fall as generics enter the market.
The layoffs are effective July 1.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
